To address the prognostic value of minimal residual disease (MRD) before unrelated cord blood transplantation (UCBT) in children with acute lymphoblastic leukemia (ALL), we analyzed 170 ALL children transplanted in complete remission (CR) after myeloablative conditioning regimen. In all, 72 (43%) were in first CR (CR1), 77 (45%) in second CR (CR2) and 21 (12%) in third CR (CR3). The median interval from MRD quantification to UCBT was 18 days. All patients received single-unit UCBT. Median follow-up was 4 years. Cumulative incidence (CI) of day-60 neutrophil engraftment was 85%. CI of 4 years relapse was 30%, incidence being lower in patients with negative MRD before UCBT (hazard ratio (HR) ¼ 0.4, P ¼ 0.01) and for those transplanted in CR1 and CR2 (HR ¼ 0.3, P ¼ 0.002). Probability of 4 years leukemia-free survival (LFS) was 44%, (56, 44 and 14% for patients transplanted in CR1, CR2 and CR3, respectively (P ¼ 0.0001)). Patients with negative MRD before UCBT had better LFS after UCBT compared with those with positive MRD (54% vs 29%; HR ¼ 2, P ¼ 0.003). MRD assessment before UCBT for children with ALL in remission allows identifying patients at higher risk of relapse after transplantation. Approaches that may decrease relapse incidence in children given UCBT with positive MRD should be investigated to improve final outcomes.
INTRODUCTION
Nowadays, intensive and risk-adapted chemotherapy protocols may cure more than 80% of children with acute lymphoblastic leukemia (ALL). [1] [2] [3] Allogeneic hematopoietic stem cell transplantation from either related or unrelated donor remains indicated either for patients in first complete remission (CR) but at very high risk of relapse or for patients who experience leukemia recurrence. 4 Unrelated cord blood transplantation (UCBT) has been explored as an alternative option for patients without a suitable human leukocyte antigen (HLA)-matched donor. 5 Tolerance of some degree of HLA mismatch, with relatively low rates of both acute and chronic graft versus host disease (GvHD), makes UCBT an attractive option for children. 6 Comparable probability of leukemia-free survival (LFS) has been reported in children with acute leukemia receiving either unrelated allele-matched bone marrow transplantation (BMT) or 1 or 2 loci mismatched UCBT. 7 Degree of minimal residual disease (MRD) after induction chemotherapy has been identified as an independent prognostic factor of outcome in childhood ALL and some reports showed that the prognostic value of MRD might overcome that of other biological and clinical variables with widely recognized predictive significance. 8, 9 Owing to its strong predictive value, MRD is being used as a tool for risk stratification in most ALL treatment protocols for both children and adults. [10] [11] [12] Different techniques are available for monitoring MRD, based either on PCR or multiparametric flow cytometry (MFC). 13, 14 Several studies have demonstrated that PCR assays and flow cytometry give complementary results in detecting residual leukemic cells and are currently employed for identification of residual disease and surveillance of disease remission. 15, 16 The threshold levels for MRD vary according to the methodology used and to the treatment protocol; however, in most studies, MRD positivity is defined by the presence of X0.01% ALL cells in the marrow. 15, 17 New markers for MRD detection in ALL have been recently identified that allow the detection of one leukemic cell among 10 À 5 cells. 18 The impact of MRD evaluation performed before allogeneic, either related or unrelated hematopoietic stem cell transplantation has been reported in patients with ALL and acute myeloid leukemia and found to be associated with outcomes. 19, 20 In order to verify whether MRD determination before the allograft has prognostic significance in patients given UCBT, we conducted a retrospective analysis on children with ALL transplanted from an unrelated cord blood donor and reported to the Eurocord registry.
PATIENTS AND METHODS

Study design and MRD definition
The following inclusion criteria were used: (i) age o18 years, (ii) diagnosis of ALL in morphological CR, and (iii) MRD testing performed before transplantation. Available data were extracted from the Eurocord registry, and additional data were collected directly from clinical records at the transplant centers. Data on patient and graft characteristics, as well as on outcomes were collected using the Eurocord forms (100 days report and yearly follow-up forms). For the purpose of this study, each transplant center was requested to complete missing data and update patient's follow-up. MRD quantification was performed on bone marrow samples, either by PCR techniques, such as antigen receptor or immunoglobulin gene rearrangement, and expression of fusion genes, or by MFC. MRD positivity was defined according to treatment protocols of the various participating centers: MRD load X10 À 3 leukemic cells was used as threshold for positivity in 34% of cases, and a load of X10 À 4 leukemic cells in the remaining 66%. Data on MRD after UCBT were not collected. All participating transplant centers received the synopsis of the study and gave their written approval. The Institutional Review Boards of the Eurocord-Netcord scientific committee approved this study. According to EBMT rules, patients gave informed consent for data entry into the EBMT and Eurocord registry database and use for analysis in accordance with the Declaration of Helsinki.
Patients
From 2000 to 2009, 316 children and adolescents with ALL in morphological CR underwent UCBT in EBMT centers and were reported to the Eurocord registry. All patients received a single unmanipulated cord blood unit as their first graft, after a myeloablative conditioning regimen (MAC). MAC was defined as a regimen containing either total body irradiation (TBI) with a dose 46 Gy, a dose of oral busulfan 48 mg/kg, a dose of intravenous busulfan 46.4 mg/kg, or a dose of treosulfan of at least 12 g/m 2 . Among these patients, 170 were assessed for MRD before UCBT and were considered in this analysis. Clinical characteristics of the study population (that is, children with available MRD value before transplantation) did not differ from those of the total cohort of patients with ALL given UCBT, confirming a representativeness of the investigated samples (data not shown).
Endpoints
Overall survival (OS) was calculated from the date of UCBT until death or last observation alive. LFS was calculated from the date of UCBT until relapse or last disease-free follow-up. Relapse and death from any cause were considered events. NRM was defined as death without prior relapse. Other endpoints included neutrophil recovery, defined as achieving absolute neutrophil count X0.5 Â 10 9 /l for 3 consecutive days, and platelet recovery, defined as achieving platelet count X20 Â 10 9 /l unsupported by platelet transfusions for 7 days. Full donor chimerism was defined as X95% leukocytes of donor origin in peripheral blood or marrow samples, measured by different techniques according to transplant centers. Autologous reconstitution was defined as X95% leukocytes of recipient origin. Mixed chimerism was defined by the presence of 45% but o95% of leukocytes of donor origin. The diagnosis and grading of acute and chronic GvHD was assigned by the transplant center using standard criteria. 21, 22 Statistical analysis Median values and ranges were used for continuous variables and percentages for categorical variables (Table 1) . For each continuous variable, the study population was initially split into quartiles and in two groups by the median. The median value was found to be the best cutoff for analysis of outcomes with one exception: for the analysis of engraftment, the CD34 þ cell dose was split using the lower quartile as cutoff (CD34 þ cells 41 Â 10 5 /kg). The probabilities of OS and LFS were calculated using the Kaplan-Meier method and the log-rank test for univariate comparisons. 23 The probabilities of neutrophil engraftment, grade II-IV acute and chronic GvHD, relapse and NRM were calculated with the CI estimator. Multivariate analyses were performed using Cox proportional hazards regression model for LFS and OS, and Fine and Gray's proportional hazards regression model. 24, 25 Variables that reached a P-value of 0.15 in the univariate analysis were included in the initial models and variables were eliminated one at a time in a stepwise fashion in order to only keep variables that reached a P-value of p0.05 in the final model.
P-values were two-sided. Statistical analyses were performed with SPSS (SPSS Inc., Chicago, IL, USA) and Splus (MathSoft, Inc., Seattle, WA, USA). Table 1 describes patients and transplant characteristics. The median age at UCBT was 6.5 years (range o1-17 years). A total of 72 patients (43%) were in first CR1 at time of UCBT, 77 (45%) were in CR2 and 21 (12%) in CR3. Among 72 patients transplanted in CR1, 56% had poor risk cytogenetics (t(4;11) or t(9;22)). Unfortunately, we do not have all the necessary information for the indication of cord blood transplantation in ALL CR1; however, as the transplant centers follow their national protocols and EBMT recommendations, we speculate that only children within the group of very high-risk ALL, defined by cytogenetic, MRD status and time to treatment response, were transplanted in CR1. In CR1 the median interval from diagnosis to UCBT was of 6, 8 months (range 2-16 months). For patients in CR2 and CR3, the median interval between remission and relapse was 22 months (range 1.6-70 months) and the median interval from the remission and UCBT was of 110 days (range 14-212 days) for the 77 patients in CR2 and was of 96 days (range 14-163 days) for the 21 patients in CR3. Patient, disease and transplantation-related factors were not statistically different between patients with MRD þ and MRD À ( Table 1 ). All patients received a TBI-based (63%) or a Busulfanbased (37%) MAC regimen. Cyclosporine in combination with corticosteroids was the most frequently used GvHD prophylaxis (75% of cases). Overall, 60% of cord blood units had 0-1 HLA mismatches with recipients and 40% had 2-3 mismatches (antigen level for HLA-A and B, allelic level for DRB1). Median infused total nucleated cell (TNC) dose was 4.8 Â 10
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7 /kg (range 1.30-18 Â 10 7 /kg) and median CD34 þ cell dose was 1.8 Â 10 5 /kg (range 1-10 Â 10 5 /kg). The median follow-up time was 4 years ranging from 4 months to 9 years (only two patients having a follow-up of o1 year: one 4 months, and the other 11.8 months).
MRD methodology and quantification MRD before UCBT was negative (MRD À ) in 96 patients (56%) and positive (MRD þ ) in 74. Among the 74 MRD þ patients, 28 were MRD þ with a threshold of MRD load X10 À 3 , and 46, X10 À 4 . In the subgroup of patients in CR1 with unfavorable cytogenetics (36 of the 43 transplanted in CR1), 16 (48%) were MRD þ , and of the 27 patients in CR2 or CR3 with unfavorable cytogenetics, 14 (52%) had a detectable MRD before UCBT. According to the different participating centers, MRD quantification was performed by PCR in 70% of cases (n ¼ 119) and by MFC in 30% (n ¼ 51) ( Table 2 ). Among the patients tested by PCR, MRD was detected using the antigen receptor rearrangement in 34% of cases, the immunoglobulin gene rearrangement in 42%, and expression of gene fusion in 23%.
The median interval from MRD quantification to UCBT was 18 days (range 12-42 days).
Engraftment and GvHD A total of 144 patients achieved neutrophil recovery, within a median time of 25 days (range 12-58 days). The CI of neutrophil recovery at day 60 was 85 ± 3% (Table 3) . Among these 144 patients, chimerism studies were performed and reported in 111 patients: 105 patients (95%) had full donor chimerism, 6 patients (5%) had mixed chimerism. Out of the 26 patients who did not engraft, 9 were alive at last follow-up. Among them, three patients had received a second transplant: one was alive and in remission at 5 years follow-up, after receiving allogeneic peripheral blood stem cells from an unrelated donor on day þ 70, and the other two patients were alive at 6.5 and 8 years follow-up, respectively, after receiving an autologous rescue.
The remaining 17 non-engrafted patients died at a median of 80 days after UCBT (range 11-550 days), including 5 patients who had received a second transplant as rescue for graft failure (3 received a second UCBT, 1 had peripheral blood stem cells from a matched-unrelated donor and 1 from a haploidentical relative donor).
In univariate analysis, CI of neutrophil recovery was higher in patients who received an infused CD34 þ cell dose X1 Â 10 5 /kg (P ¼ 0.03) and in patients who received an infused TNC dose X4.8 Â 10 7 /kg (P ¼ 0.02). On multivariate analysis, the only factor independently associated with neutrophil recovery was the 
A total of 111 patients reached a platelet count X20 Â 10 9 /l at a median of 42 days (range 11-250 days). The CI of platelet recovery at day 180 was 71 ± 4%.
Overall, 58 patients developed grade II-IV acute GvHD: 39 patients experienced grade II, 14 grade III and 5 grade IV. The day 100 CI of acute GvHD was 26 ± 4%, with a median of 22 days to the onset of acute GvHD. In all, 24 patients developed chronic GvHD: 15 of them with a limited involvement, and 9 with extensive involvement. The overall incidence of chronic GvHD at 4 years was 17%.
Relapse At 4 years, the overall CI of relapse was 30±3% (Table 3 ). In all, 52 patients relapsed within a median time of 6 months after UCBT (range 1-38 months). The distribution of disease status at UCBT was as following: 17 out of 72 patients transplanted in CR1 relapsed (CI at 4 years 23±4%), 26 out of 77 patients transplanted in CR2 (CI at 4 years 34 ± 5%), and 9 out of 21 patients transplanted in CR3 (CI at 4 years 42±8%) (Po0.001). With regard to the method used for MRD quantification, 37 (22 were MRD þ and 15 MRD À ) of 119 patients studied by PCR relapsed, as well as 15 of 51 patients tested by MFC (10 were MRD þ and 5 MRD À ). In univariate analysis, a lower relapse incidence at 4 years was observed in patients having a negative MRD before UCBT when compared with those with a positive MRD (24 ± 3% vs 39±6%, P ¼ 0.05) (Figure 1) , and in patients receiving a TBI-based regimen (28% vs 38% with other regimens, P ¼ 0.08). Among the 74 MRD þ patients, the risk of relapse was 38% for those with MRD levels of X10 À 3 (n ¼ 28), and it was 46% for those X10 Abbreviations: NRM means non relapse mortality; LFS, leukemia free survival; OS, overall survival; UCBT, unrelated cord blood transplantation; CR, complete remission; MRD, minimal residual disease; HLA, human leukocyte antigen; TBI, total body irradiation; ATG, anti-thymocyte globulin; TNC, total nucleated cell.
After multivariate analysis adjusted for patient's age, cytogenetic risk group and TBI-based MAC, positive MRD before UCBT was an independent factor statistically associated with higher relapse incidence (HR ¼ 2.15, P ¼ 0.01). Also, relapse incidence was higher for patients transplanted in CR3 (HR ¼ 4.25, P ¼ 0.002) ( Table 4) .
Non-relapse mortality At 4 years, the overall CI of NRM was 22 ± 3%. Factors associated with a decreased incidence of NRM in univariate analysis were as follows: (1) younger age at UCBT (o6.5 years) (19% vs 32%, P ¼ 0.05), (2) CR1 or CR2 at transplantation (23% vs 43%, P ¼ 0.02) and (3) TNC dose 44.8 Â 10 7 /kg (18% vs 33%, P ¼ 0.005). In multivariate analysis, MRD status was not associated with NRM, but other factors such as a TNC dose 44.8 Â 10 7 /kg (HR: 0.46, P ¼ 0.03) and being in CR1 or CR2 (HR: 3.13, P ¼ 0.009) were factors independently associated with lower NRM (Table 4) .
Leukemia-free survival, overall survival The 4-year probability of LFS was 44 ± 4%. In the univariate analysis, the following variables were associated with a higher LFS: disease status at time of the allograft (56±6% for patients in CR1, 44±5% for patients in CR2, and 14±7% for patients in CR3, (P ¼ 0.0001), and negative MRD before UCBT (54 ± 4% vs 29 ± 6%, P ¼ 0.006). LFS at 4 years was 47 ± 5% for patients with MRD quantification performed by PCR and 43±9% for those studied by MFC (P ¼ ns).
When stratifying according to disease status at time of the allograft and MRD, for patients in CR1, CR2 and CR3 LFS was 63%, 53% and 20% in MRD À and 42%, 27% and 10% in MRD þ groups, respectively.
In multivariate analysis adjusted, MRD þ before UCBT and disease status at transplantation were independent factors statistically associated with decreased LFS (MRD status: HR ¼ 0.5, P ¼ 0.003, disease status: HR ¼ 3.7, Pp0.0001) (Table 4, Figure 2 ).
For the whole cohort of patients studied, the probability of OS at 4 years was 51±4%. There were a total of 81 deaths, 47 due to transplant-related events and 34 due to relapse. Causes of death did not differ according to MRD status. Overall, 19 out of the 96 patients with MRD died of relapse and 15 of the 74 patients transplanted with MRD þ . Factors associated with OS were similar to those for LFS: disease status at time of the allograft (62% for patients in CR1, 48% for patients in CR2, and 24% for patients in CR3, (P ¼ 0.0001), and negative MRD before UCBT (58% vs 42%, P ¼ 0.004). OS was also found to improve over time, with an OS at 4 years of 48% for patients transplanted before 2005 and 56% for those after 2006 (P ¼ 0.07).
DISCUSSION
In this retrospective registry-based study, we investigated the significance of MRD in ALL children transplanted in remission from an unrelated cord blood donor. To this date, the impact of MRD before transplantation in childhood ALL has only been addressed in studies with a relatively small number of patients. 19, 26, 27 In this study, including 170 patients with a median follow-up of 4 years, we have shown that MRD before UCBT is a strong predictive Leukemia Free Survival Figure 2 . The estimated 4-year probability of LFS in children with ALL in remission by MRD status before UCBT. The 4-year probability of LFS for children with pretransplant MRD þ and MRD À was 29% and 54%, P ¼ 0.006, respectively. factor for increasing relapse rate and decreasing LFS after UCBT. Thus, we have confirmed the important relationship between pretransplantation MRD and outcomes following allogeneic hematopoietic stem cell transplantation, already reported in other studies focusing on different transplant settings. [28] [29] [30] [31] These findings may have important implications in the management of patients before and after transplantation with the objective of improving final outcomes. Nevertheless, owing to its retrospective and multicenter characteristics, our study has some limitations. We could not define a MRD burden cutoff, as previously done in prospective and single centers studies due to lack of homogeneous techniques and different thresholds adopted for MRD assessment. Nonetheless, even if the techniques used to detect MRD may vary, some authors have shown that MFC-and PCR-based detection methods in ALL provides concordant results in the vast majority of cases. 32 In our analysis, we confirmed that the presence of detectable MRD assessed either by PCR (n ¼ 119) or by MFC (n ¼ 51) was statistically associated with LFS (PCR: P ¼ 0.02, MFC: P ¼ 0.05) and relapse (PCR: P ¼ 0.04, MFC: P ¼ 0.01).
Moreover, despite the absence of uniform MRD threshold, our findings confirm results obtained in prospective and single-center analysis. In fact, Bader et al. 19 analyzed MRD by PCR in 91 children with ALL, finding that the 5-year event-free survival probability was 27% in those with a MRD value of 10 À 4 or more, compared with 60% in those with a MRD value of o10 À 4 . Others 27 reported 31 children with ALL in remission studied by MFC. Although with the limitation of a short follow-up (9 months), they showed a higher relapse incidence in the 10 patients with positive MRD as compared with 21 patients with undetectable MRD.
The data presented in our analysis showed that MRD þ patients had significantly worse outcomes, with a 4-year CI of relapse of 39%, which resulted in decreased LFS, when compared with MRD patients. It may be worthy to note the kinetics of relapse occurrences shown in Figure 1 , that the survival curves begin to separate at around 6 months after UCBT. We may speculate that this observation might be indicative of some disease control by the donor. The multivariate model for relapse incidence and LFS suggested that MRD positivity before UCB is an adverse risk factor independent of other factors, including cytogenetics. It is largely accepted that translocations t(4;11) and t(9;22) identify patients at high risk of treatment failure. 33, 34 In our analysis, LFS at 4 years did not differ among the 63 patients with unfavorable and the 85 patients with favorable or intermediate cytogenetics (47% vs 52%, P ¼ 0.23).
Although patients at high risk of relapse can be identified using MRD before transplantation, little is known on how to prevent relapse using experimental or established approaches both before and after transplantation. We were unable to identify prognostic factors that could be associated with better outcomes in the 74 MRD þ patients, probably due to lack of statistical power (data not shown).
Many hypotheses can be considered to improve outcomes of patients MRD positivity before allogeneic transplantation. These include pretransplantation treatment aimed at decreasing MRD levels with new drugs, such as clofarabine 35, 36 and nelarabine 37 used in combination with other cytotoxic agents, use of the anti-CD19/antiCD3 bi-specific monoclonal antibody blinatunomab, 38 use of midostaurin for MLL rearranged ALL cases, or use of tyrosine kinase inhibitors for Ph-positive ALL. 39 Less intensive GvHD prophylaxis, rapid withdrawal of immunosuppression, 40 cell-based immunotherapy 41, 42 (that is, leukemia-reactive cytotoxic T cells) or use of double UCBT 43, 44 can also be useful in the perspective of increasing the GVL effect. However, only well-designed prospective trials may provide sound evidence on the efficacy of these approaches.
